Maria Cristina Miggiano
A5050861691- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Lymphoblastic Leukemia research
- HER2/EGFR in Cancer Research
- Fungal Plant Pathogen Control
- Synthesis of Tetrazole Derivatives
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Synthesis and biological activity
- Peptidase Inhibition and Analysis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Hematological disorders and diagnostics
- Lung Cancer Treatments and Mutations
- Click Chemistry and Applications
- Ferrocene Chemistry and Applications
- Chemotherapy-related skin toxicity
- COVID-19 and healthcare impacts
Ospedale San Bortolo
2017-2024
Istituto Oncologico Romagnolo
1992
Abstract Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival CML patients has become very close to normal. The next, ambitious, step is bring as many possible into a condition treatment-free remission (TFR). Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA; Italian Group for Hematologic Diseases Adult) Working Party (WP) developed project aimed at...
TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, dose reduction is often used prevent AEs. However, data on its impact successful treatment-free remission (TFR) are quite scarce. We conducted a retrospective study the outcome of subjects who discontinued low-dose from 54 Italian hematology centers participating Campus network. Overall, 1.785 5.108 (35.0%) regularly followed patients were treated with...
Summary Limited information is available on the impact of COVID‐19 pandemic management chronic myeloid leukaemia (CML). The Campus CML network collected retrospective 8 665 patients followed at 46 centres throughout Italy during between February 2020 and January 2021. Within this cohort, we recorded 217 SARS‐CoV‐2‐positive (2·5%). Most (57%) were diagnosed as having SARS‐CoV‐2 infection second peak (September to 2021). majority (35%) was aged 50 65 years with a male prevalence (73%)....
Treatment-free remission (TFR) has become a primary therapeutic goal in CML and is also considered feasible by international guidelines. TKIs dose reduction often used real-life practice to reduce adverse events, although its impact on TFR still matter of debate. This study aimed explore the attitude Italian hematologists towards prescribing at reduced doses TFR. In September 2020, questionnaire was sent 54 hematology centers Italy participating Campus network. For each patient, data main...
Abstract Background The authors assessed the clinical utility of patient‐reported symptom monitoring in setting newly diagnosed chronic myeloid leukemia (CML). primary objective was to evaluate adherence therapy. Methods conducted an international prospective study that included patients with diagnosed, chronic‐phase CML. Before consultation, were provided a tablet computer self‐rate their symptoms, and results available real time each physician during patient’s visit. Adherence by pill...
Abstract Background Patients with hematological malignancies are at an increased risk of SARS‐CoV‐2 disease (COVID‐19) and adverse outcome. However, a low mortality rate has been reported in patients chronic myeloid leukemia (CML). Preclinical evidence suggests that tyrosine kinase inhibitors (TKIs) may have protective role against severe COVID‐19. Methods We conducted cross‐sectional study 564 consecutive CML who were tested for anti‐SARS‐CoV‐2 IgG/IgM antibodies their first outpatient...
ABSTRACT Objectives The study aimed to evaluate the utilization of frontline TKI therapy in a large cohort elderly CP‐CML patients. Methods A retrospective analysis was conducted on 332 patients aged 75 years or older among 1929 diagnosed from January 2012 December 2019 followed at 36 participating Hematology Centers involved “Campus CML” project. Results Among analyzed, 85.8% received imatinib (IM) while 14.2% second‐generation TKIs (2G‐TKI), 59.5% dasatinib, and 40.5% nilotinib. Most...
Imatinib, dasatinib, and nilotinib are tyrosine kinase inhibitors (TKIs) approved in Italy for frontline treatment of chronic-phase chronic myeloid leukemia (CP-CML). The choice TKI is based on a combined evaluation the patient's disease characteristics. aim this study was to analyze use therapy an unselected cohort Italian patients with CP-CML correlate features.A total 1967 diagnosed between 2012 2019 at 36 centers throughout were retrospectively evaluated; 1089 (55.4%) received imatinib...
Health-related quality of life (HRQOL) assessment is important to facilitate decisions in the current treatment landscape chronic myeloid leukemia (CML). Therefore, availability a validated HRQOL questionnaire, specifically developed for CML patients treated with tyrosine kinase inhibitors (TKIs), may enhance research this area. We performed an international study including 782 assess validity EORTC QLQ-CML 24 and generate reference values interpretation results future studies. Internal...
An observational prospective study was conducted by the CML Italian network to analyze role of baseline patient characteristics and first line treatments on overall survival CML-related mortality in 1206 newly diagnosed patients, 608 treated with imatinib (IMA) 598 2 nd generation tyrosine kinase inhibitors (2GTKI). IMA-treated patients were much older (median age 69 years, IQR 58-77) than 2GTKI group (52, 41-63) had more comorbidities. Estimated 4-year entire cohort 89% (95%CI 85.9-91.4)....
Disease progression to accelerated/blast phase (AP/BP) in patients with chronic myeloid leukemia (CP-CML) after treatment discontinuation (TD) has never been systematically reported clinical trials. However, recent reports of several such cases raised concern. To estimate the risk AP/BP among TD-eligible patients, we conducted TFR-PRO, a cohort retro-prospective study: 870 CP-CML eligible for TD formed (505 patients) and reference one (365 patients). The primary objective was time adjusted...
Background: Asciminib (Asc) is the first tyrosine kinase inhibitor (TKI) to Specifically Target ABL Myristoyl Pocket (STAMP). The recent update of ASCEMBL study demonstrated a superior efficacy with good tolerability Asc compared bosutinib in chronic phase myeloid leukemia (CP-CML) patients intolerant or refractory ≥2 TKIs (major molecular response (MMR) rate at week 96: 37.6% vs 15.8%; treatment discontinuation 7.7% 26.3%) (Rea et al, 2022) Aims: Here we present real-world clinical outcomes...
In chronic-phase chronic myeloid leukemia (CML), tyrosine kinase inhibitors (TKIs) are the standard of care, and treatment-free remission (TFR) following achievement a stable deep molecular response (DMR) has become, alongside survival, primary goal for virtually all patients. The GIMEMA CML working party recently suggested that possibility achieving TFR cannot be denied to any patient, proposed specific treatment policies according patient's age risk. However, other international...